PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR), Inc.
Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible combination, which may include an offer for the share capital of PureTech.
“PureTech and Nektar remain in discussions regarding the proposal. There can be no certainty that any firm offer will be made, nor as to the terms of any such offer. A further announcement will be made as and when appropriate,” the clinical-stage biotherapeutics company said.